Invention Grant
US07642261B2 Use of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and its physiologically acceptable salts
有权
1- [4-(5-氰基吲哚-3-基)丁基] -4-(2-氨基甲酰基 - 苯并呋喃-5-基) - 哌嗪及其生理上可接受的盐
- Patent Title: Use of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and its physiologically acceptable salts
- Patent Title (中): 1- [4-(5-氰基吲哚-3-基)丁基] -4-(2-氨基甲酰基 - 苯并呋喃-5-基) - 哌嗪及其生理上可接受的盐
-
Application No.: US11946149Application Date: 2007-11-28
-
Publication No.: US07642261B2Publication Date: 2010-01-05
- Inventor: Gerd Bartoszyk , Christoph Seyfried , Christoph Von Amsterdam , Henning Boettcher , Ewen Sedman
- Applicant: Gerd Bartoszyk , Christoph Seyfried , Christoph Von Amsterdam , Henning Boettcher , Ewen Sedman
- Applicant Address: DE Darmstadt
- Assignee: Merck Patent GmbH
- Current Assignee: Merck Patent GmbH
- Current Assignee Address: DE Darmstadt
- Agency: Millen, White, Zelano, Branigan, P.C.
- Main IPC: A61K31/497
- IPC: A61K31/497
![Use of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and its physiologically acceptable salts](/abs-image/US/2010/01/05/US07642261B2/abs.jpg.150x150.jpg)
Abstract:
1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or a physiologically acceptable salt thereof is used for the manufacture of a medicament for the treatment of sub-type anxiety disorders chosen from the sub-types panic disorder with or without agoraphobia, agoraphobia obsessive-compulsive spectrum disorders, social phobia, posttraumatic stress disorder, acute stress indication or generalized-anxiety disorder, bipolar disorders, mania, dementia substance-related disorders, sexual dysfunctions, eating disorders, obesity, anorexia and fibromyalgia. A preferred salt is 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride.
Public/Granted literature
Information query
IPC分类: